Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma

Shu-Sheng Wu; Jian Chen; Ying Yan; Hui-Qin Luo; Wen-Ju Chen; Yi-Fu He

doi:10.3892/ol.2020.11778

Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma

Oncol Lett. 2020 Sep;20(3):2209-2216. doi: 10.3892/ol.2020.11778. Epub 2020 Jun 25.

Authors

Shu-Sheng Wu^{1

2}, Jian Chen³, Ying Yan^{1

2}, Hui-Qin Luo^{1

2}, Wen-Ju Chen^{1

2}, Yi-Fu He^{1

2

3}

Affiliations

¹ Department of Oncology, West District of The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230031, P.R. China.
² Department of Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
³ Department of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, P.R. China.

Abstract

The present study compared the expression levels of limb-bud and heart (LBH) between gastric intestinal-type adenocarcinoma (GITA) and healthy gastric tissues; with the aim of investigating the possible effect of LBH on the prognosis of patients with GITA and to analyze the associated signaling pathways in GITA. Three Oncomine gastric datasets were utilized for the preliminary prediction of the expression levels of LBH mRNA in GITA and healthy gastric tissues. Gene expression and corresponding clinical data of 163 patients with GITA were downloaded from The Cancer Genome Atlas. Wilcoxon signed rank-sum test was used to distinguish the clinical value of LBH expression in the various clinicopathological features. Subsequently, Kaplan-Meier univariate and Cox multivariate survival analyses were performed to determine the prognostic significance of LBH expression in patients with GITA. Function enrichment analysis was conducted for the co-expression gene of LBH, defined as correlation coefficient r>0.06 and P<0.05 using Pearson's χ² test. Bioinformatics data demonstrated that compared with that in the normal gastric mucosa, LBH mRNA expression was dramatically higher in GITA tissues (P<0.05). There were significant relationships between the differential expression levels of LBH and clinicopathological parameters in GITA patients (all p<0.05), including pathological stage T (T3-4 vs. T1-2), lymph node metastasis (no vs. yes), distant metastasis (no vs. yes), histological grade (grade 3 vs. grades 1-2) and tumor stage (stages 3-4 vs. stages 1-2). Additionally, the overall survival and disease-free survival (DFS) of patients in the high expression group were poorer compared with those in the low expression group (P<0.05). Cox multivariate survival analysis indicated that increased LBH expression was an independent predictor of poor DFS prognosis in patients with GITA (P=0.045). In summary, LBH is highly expressed in GITA, which can be used as an independent predictor of poor prognosis in patients with GITA. LBH co-expressed genes are closely associated with GITA tumor migration and metastasis.

Keywords: The Cancer Genome Atlas; bioinformatics; biomarker candidates; limb-bud and heart; stomach neoplasms.